electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Company profile
Ticker
ECOR
Exchange
Website
CEO
Mr. Daniel S. Goldberger
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ElectroCore, LLC
SEC CIK
Corporate docs
Subsidiaries
electroCore Germany GmbH • electroCore UK Ltd. ...
ECOR stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
6 Sep 24
10-Q
2024 Q2
Quarterly report
7 Aug 24
8-K
Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023
7 Aug 24
D
$0.00 in other securities
2 Aug 24
424B3
Prospectus supplement
23 Jul 24
EFFECT
Notice of effectiveness
23 Jul 24
S-1/A
IPO registration (amended)
18 Jul 24
DEF 14A
Definitive proxy
17 Jul 24
8-K
Departure of Directors or Certain Officers
17 Jul 24
S-1
IPO registration
10 Jul 24
Transcripts
ECOR
Earnings call transcript
2024 Q2
7 Aug 24
ECOR
Earnings call transcript
2023 Q3
8 Nov 23
ECOR
Earnings call transcript
2023 Q2
9 Aug 23
ECOR
Earnings call transcript
2023 Q2
9 Aug 23
ECOR
Earnings call transcript
2023 Q1
3 May 23
ECOR
Earnings call transcript
2022 Q4
8 Mar 23
ECOR
Earnings call transcript
2022 Q3
3 Nov 22
ECOR
Earnings call transcript
2022 Q2
7 Aug 22
ECOR
Earnings call transcript
2022 Q1
9 May 22
ECOR
Earnings call transcript
2021 Q4
11 Mar 22
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.55 mm | 10.55 mm | 10.55 mm | 10.55 mm | 10.55 mm | 10.55 mm |
Cash burn (monthly) | 1.80 mm | (no burn) | 885.00 k | 1.22 mm | 590.67 k | 818.83 k |
Cash used (since last report) | 5.01 mm | n/a | 2.47 mm | 3.40 mm | 1.65 mm | 2.28 mm |
Cash remaining | 5.54 mm | n/a | 8.08 mm | 7.15 mm | 8.91 mm | 8.27 mm |
Runway (months of cash) | 3.1 | n/a | 9.1 | 5.9 | 15.1 | 10.1 |
Institutional ownership, Q1 2024
29.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 19 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 2.45 bn |
Total shares | 1.92 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Core Ventures II | 920.03 k | $1.44 mm |
Theofilos Charles Steve | 536.47 k | $2.98 mm |
Vanguard | 161.71 k | $997.72 mm |
Renaissance Technologies | 66.52 k | $410.00 k |
International Assets Investment Management | 53.02 k | $324.48 mm |
Geode Capital Management | 52.61 k | $324.69 mm |
Sontag Advisory | 47.50 k | $293.06 mm |
Jaffetilchin Investment Partners | 26.28 k | $162.17 mm |
PFG Investments | 18.00 k | $111.06 mm |
ARS Investment Partners | 12.14 k | $74.88 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Sep 24 | Theofilos Charles Steve | Common Stock | Grant | Acquire A | No | No | 0 | 16,582 | 0.00 | 454,202 |
3 Sep 24 | John P Gandolfo | Common Stock | Grant | Acquire A | No | No | 0 | 16,583 | 0.00 | 67,287 |
3 Sep 24 | Patton Thomas M | Common Stock | Grant | Acquire A | No | No | 0 | 16,583 | 0.00 | 83,771 |
3 Sep 24 | Patricia Wilber | Common Stock | Grant | Acquire A | No | No | 0 | 16,583 | 0.00 | 49,697 |
3 Sep 24 | Errico Thomas J. | Common Stock | Grant | Acquire A | No | No | 0 | 16,583 | 0.00 | 250,401 |
Press releases
Study Suggests Non-invasive Vagus Nerve Stimulation (nVNS) is effective in accelerating United States Air Force Pilot Training
10 Sep 24
electroCore to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
4 Sep 24
Ecora Resources PLC Announces Half year results
4 Sep 24
electroCore Announces Second Quarter 2024 Financial Results
7 Aug 24
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
2 Aug 24